408 related articles for article (PubMed ID: 26627075)
1. Brodalumab versus ustekinumab in psoriasis.
Fioranelli M; Roccia MG; Lotti T
Dermatol Ther; 2016 Sep; 29(5):298. PubMed ID: 26627075
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of brodalumab in patients with psoriasis who had inadequate responses to ustekinumab: subgroup analysis of two randomized phase III trials.
Langley RG; Armstrong AW; Lebwohl MG; Blauvelt A; Hsu S; Tyring S; Rastogi S; Pillai R; Israel R
Br J Dermatol; 2019 Feb; 180(2):306-314. PubMed ID: 30328108
[TBL] [Abstract][Full Text] [Related]
3. Erythrodermic psoriasis and secukinumab: Our clinical experience.
Mateu-Puchades A; Santos-Alarcón S; Martorell-Calatayud A; Pujol-Marco C; Sánchez-Carazo JL
Dermatol Ther; 2018 Jul; 31(4):e12607. PubMed ID: 29663615
[No Abstract] [Full Text] [Related]
4. Treatment of psoriasis and psoriatic arthritis with secukinumab after unsatisfactory response to ustekinumab in multiple sclerosis patient.
Assefa GT; Kaneko S; Oguro H; Morita E
J Dermatol; 2019 Mar; 46(3):e112-e113. PubMed ID: 30151838
[No Abstract] [Full Text] [Related]
5. Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials.
Gottlieb AB; Gordon K; Hsu S; Elewski B; Eichenfield LF; Kircik L; Rastogi S; Pillai R; Israel R
J Eur Acad Dermatol Venereol; 2018 Aug; 32(8):1305-1313. PubMed ID: 29512200
[TBL] [Abstract][Full Text] [Related]
6. Brodalumab: the first anti-IL-17 receptor agent for psoriasis.
Puig L
Drugs Today (Barc); 2017 May; 53(5):283-297. PubMed ID: 28650001
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and skin clearance recapture in clinical studies of brodalumab.
Bagel J; Lebwohl M; Israel RJ; Jacobson A
J Am Acad Dermatol; 2020 Feb; 82(2):344-351. PubMed ID: 31175910
[TBL] [Abstract][Full Text] [Related]
8. The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis.
Sawyer L; Fotheringham I; Wright E; Yasmeen N; Gibbons C; Holmen Møller A
J Dermatolog Treat; 2018 Sep; 29(6):557-568. PubMed ID: 29323542
[TBL] [Abstract][Full Text] [Related]
9. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis.
Fioranelli M; Roccia MG; Lotti T
Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28508536
[No Abstract] [Full Text] [Related]
10. Ustekinumab in severe complicated erythrodermic psoriasis: rapid clearing, safety, and sustained remission.
Koutsoukou XA; Papadavid E; Theodoropoulos K; Rigopoulos D
Dermatol Ther; 2014; 27(5):257-9. PubMed ID: 24813816
[TBL] [Abstract][Full Text] [Related]
11. Ustekinumab for psoriasis and psoriatic arthritis.
Goldminz AM; Gottlieb AB
J Rheumatol Suppl; 2012 Jul; 89():86-9. PubMed ID: 22751602
[TBL] [Abstract][Full Text] [Related]
12. Long-term remission induced by secukinumab in a 13-year-old boy having recalcitrant chronic erythrodermic psoriasis.
Dogra S; Bishnoi A; Narang T; Handa S
Dermatol Ther; 2018 Jul; 31(4):e12611. PubMed ID: 29687662
[No Abstract] [Full Text] [Related]
13. Response of superimposed linear psoriasis to ustekinumab: A case report.
Weng HJ; Tsai TF
Indian J Dermatol Venereol Leprol; 2017; 83(3):392-396. PubMed ID: 28366906
[No Abstract] [Full Text] [Related]
14. Brodalumab: A Review in Moderate to Severe Plaque Psoriasis.
Blair HA
Drugs; 2018 Mar; 78(4):495-504. PubMed ID: 29516365
[TBL] [Abstract][Full Text] [Related]
15. Brodalumab (Siliq
Gupta AK; Versteeg SV; Abramovits W; Vincent KD
Skinmed; 2017; 15(4):281-285. PubMed ID: 28859739
[No Abstract] [Full Text] [Related]
16. Malignancy Rates in Brodalumab Clinical Studies for Psoriasis.
Gottlieb A; Lebwohl M; Liu C; Israel RJ; Jacobson A
Am J Clin Dermatol; 2020 Jun; 21(3):421-430. PubMed ID: 32207067
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil-to-lymphocyte ratio decreases after treatment of psoriasis with therapeutic antibodies.
Zhang L; Wiles C; Martinez LR; Han G
J Eur Acad Dermatol Venereol; 2017 Nov; 31(11):e491-e492. PubMed ID: 28502119
[No Abstract] [Full Text] [Related]
18. Ustekinumab (Stelara) for psoriasis.
Med Lett Drugs Ther; 2010 Jan; 52(1330):7-8. PubMed ID: 20208473
[No Abstract] [Full Text] [Related]
19. Ustekinumab.
Weber J; Keam SJ
BioDrugs; 2009; 23(1):53-61. PubMed ID: 19344192
[TBL] [Abstract][Full Text] [Related]
20. Differential response of chronic plaque psoriasis to briakinumab vs. ustekinumab.
Inzinger M; Weger W; Salmhofer W; Wolf P
Acta Derm Venereol; 2012 Jul; 92(4):357-8. PubMed ID: 22169986
[No Abstract] [Full Text] [Related]
[Next] [New Search]
